Can any hospital in China provide CAR-T or cell therapy?
Published by Lexaid, the brand of Shanghai Qile Wuyou Technology Co., Ltd. (其乐无忧). Company & brand
In brief
CAR-T in China is not available at every hospital. Separate labeled commercial use, a clinical trial, and Lecheng special access, then match the indication and the center. This page is not a diagnosis or a reserved slot. The label, ethics file, and hospital writing win.
Three actions you can take
- Freeze pathology, molecular typing, and prior lines, then compare them with the current label or trial protocol.
- Make the hospital name the path in writing: NMPA label, clinical trial, or Lecheng special/new-technology access.
- Check apheresis, manufacturing, CRS/ICANS care, and ICU backup, and get a line-item quote before you buy tickets.
What this page does not promise
- This is not a diagnosis, enrollment decision, or remission guarantee.
- It does not lock product price, trial fee waivers, or a reserved slot.
- The NMPA label, ethics approval, and receiving center’s written path win.
NMPA also operates accelerated registration tools for some cell and gene products. Those are product-level procedures, not a promise that any hospital can treat any international patient tomorrow. In July 2026 NMPA also sought comment on optimizing review—policy is still moving.
Lecheng public lists have shown price bands for some CAR-T-related items. Those are communication figures. Commercial labels and trial inclusion criteria are not interchangeable.
Who this is for
- Patients with relapsed/refractory large B-cell lymphoma, multiple myeloma, or similar records who want to check a commercial CAR-T label
- People a trial site has told, in writing, that they may meet inclusion and who need an international-admission process
- Families who want to separate a hospital path from a poster
Who this is not for
- Using cell therapy as first-line care for every solid tumor
- Itineraries that cannot cover manufacturing plus ICU-level observation
- Refusing prior-treatment and infection-screening files
- Asking a coordinator to guarantee remission
Steps
- 1
Freeze diagnosis and prior lines
Pathology (including IHC/molecular), stage, regimens and best response, major comorbidities. Commercial CAR-T labels usually specify subtype and line. If they do not match, do not book as if they did.
- 2
Make the hospital name the path
Write down: labeled commercial use, a trial, or a Lecheng-style special/new-technology path. Consent, billing, and follow-up duties differ.
- 3
Check center capability, not only the department name
Ask where apheresis happens, whether manufacturing is on-site or outsourced, ward level after infusion, CRS/ICANS protocol, ICU backup, and whether international patients are accepted. If any item is missing, the trip is not ready.
- 4
Demand an itemized quote and a stay calendar
Split work-up, apheresis, product or trial charges, bridging, post-infusion stay, possible ICU, and return visits. Ask who pays if manufacturing fails or disease progresses. Align the calendar with the visa.
- 5
Filter marketing with a short list
Keep: label or protocol indication, a center capability note, a dated quote, toxicity language in consent. Discard: no side effects, all cancers, one anecdote as proof, or “a slot is reserved” without enrollment.
Commercial, trial, Lecheng—do not mix them
Commercial use follows the label and the hospital’s prescribing authority, and can still wait on capacity or payment. Trials have protocols and ethics review; they may waive some drug cost and are not a treatment promise.
A Lecheng path follows that hospital’s approval, not an automatic nationwide label. Prices and indications can differ. See the Lecheng special-access guide.
Costs
| Costs | Notes |
|---|---|
| Product or trial-related charges | Commercial CAR-T and Lecheng list prices are different sets of numbers |
| Apheresis, logistics, bridging | Often outside the “product” line |
| Post-infusion stay and possible ICU | Monitoring days vary by center and toxicity |
| Work-up without enrollment or infusion | Agree in advance who pays |
Documents & materials
| Documents & materials | Notes |
|---|---|
| Pathology and molecular typing | Needed to match targets such as CD19 or BCMA |
| Full prior-line record | Shows whether the labeled line is met |
| Infection screen and organ assessment | Center-specific; collect before travel |
| Path letter + itemized quote + consent | All three before non-refundable tickets |
Risks
- Progression during manufacturing
- CRS/ICANS extending stay beyond the visa
- A trial or special-access project sold as routine care
- Comparing only a single “per dose” number
Confirm in writing with the hospital
- Path type and indication text
- International-patient rules and apheresis/infusion calendar
- CRS/ICANS and ICU arrangements
- Itemized fees if manufacturing or infusion does not proceed
- How many follow-up days must be spent in China
FAQ
- Has China approved commercial CAR-T?
- Yes. NMPA has approved multiple products since 2021, publicly focused on selected relapsed/refractory hematologic cancers. Use the current label and the receiving hospital.
- Can solid tumors use CAR-T?
- Most approved labels are hematologic. Solid-tumor programs are more often trials or special-access projects. Do not extrapolate from blood-cancer commercial use.
- Is “no side effects” believable?
- Not as a medical basis. Labels and guidelines discuss CRS and neurologic toxicity. The center must be able to manage them.
- Can Lexaid reserve a slot?
- We can submit records and ask about timing. Queues belong to the hospital or sponsor. A verbal hold is not a contract.
Information current as of September 2026
This page is general information for international patients considering care in China. It is not a diagnosis, treatment plan, price quote, or visa guarantee. Pathways, fees, and entry rules change by hospital and consular district.
Sources
Related guides
Need a coordinator for care in China?
Lexaid matches hospitals and specialists, helps with records, invitation letters, and on-the-ground logistics. Diagnosis and treatment stay with the hospital.